A. Tedeschi, D.H. Peng, F. Schischlik-Siegl, O. Schaaf, D. Gerlach, F. Rocchetti, J. Popow, J. Broeker, T. Wunberg, A.S. Boghossian, M.G. Rees, M.M. Ronan, J.A. Roth, M. Williams, C. Vellano, J.R. Marszalek, T.P. Heffernan, M. Pearson, N. Kraut, R. Dorothea
{"title":"100(PB088):KRAS 多种抑制剂 BI 3706674 在 KRAS 驱动的癌症临床前模型中显示出疗效,支持对携带 KRASG12V 突变和 KRAS 野生型扩增的肿瘤患者进行临床试验。","authors":"A. Tedeschi, D.H. Peng, F. Schischlik-Siegl, O. Schaaf, D. Gerlach, F. Rocchetti, J. Popow, J. Broeker, T. Wunberg, A.S. Boghossian, M.G. Rees, M.M. Ronan, J.A. Roth, M. Williams, C. Vellano, J.R. Marszalek, T.P. Heffernan, M. Pearson, N. Kraut, R. Dorothea","doi":"10.1016/j.ejca.2024.114624","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"211 ","pages":"Article 114624"},"PeriodicalIF":7.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild-type amplifications.\",\"authors\":\"A. Tedeschi, D.H. Peng, F. Schischlik-Siegl, O. Schaaf, D. Gerlach, F. Rocchetti, J. Popow, J. Broeker, T. Wunberg, A.S. Boghossian, M.G. Rees, M.M. Ronan, J.A. Roth, M. Williams, C. Vellano, J.R. Marszalek, T.P. Heffernan, M. Pearson, N. Kraut, R. Dorothea\",\"doi\":\"10.1016/j.ejca.2024.114624\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"211 \",\"pages\":\"Article 114624\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924013157\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924013157","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild-type amplifications.
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.